Almac’s Breakthrough Biomarker for Stage II/III Colon Cancer

This true example of a powerful multiplex signature involves a 634–probe set signature that can identify patients at high-risk for recurrence and/or high risk for cancer-related death.

View more

Almac’s Predictive Assay for Immuno-Oncology & DNA Damaging Agents

Almac has developed a gene expression assay to predict outcomes following treatment with DNA damaging drugs such as Anthracycline and Cyclophosphamide, novel DNA-damaging therapeutics such as PARP inhibitors as well as Immuno-Oncology agents.

View more

Almac’s Predctive Assay for Anti-Angiogenic Agents

Almac has identified and validated a powerful gene expression biomarker which identifies a molecular subgroup of patients who may benefit from anti-angiogenic therapy following standard of care chemotherapy.

View more

Almac’s Prognostic Assay for Prostate Cancer

Almac have identified a prognostic gene expression biomarker that prospectively identifies potential metastatic disease in prostate cancer patients.

Almac’s Predictive Assay for MEK Inhibitors

Almac’s gene expression biomarker utilised to predict response to MEK inhibitors across numerous disease indications which may be affected by the MEK pathway aberrations.

Contact us or give us feedback get in touch